男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
World
Home / World / Europe

WHO approves China's Sinopharm vaccine for emergency use

By Bo Leung in London | chinadaily.com.cn | Updated: 2021-05-07 23:30
Share
Share - WeChat

The World Health Organization announced on Friday it will give emergency use authorization to the COVID-19 vaccine manufactured by China's Sinopharm.

The greenlight for the Sinopharm vaccine to be rolled out globally could pave the way for millions of doses to reach needy countries and boost WHO-backed efforts such as the COVAX initiative, which is a global effort aimed at ensuring access in poorer nations to novel coronavirus vaccines.

The WHO program has already distributed over 54 million doses of COVID-19 vaccines.

The move marks the first time any Chinese-made vaccine has received emergency authorization from the WHO.

During a media briefing, the head of the WHO, Tedros Adhanom Ghebreyesus,?said: "WHO gave Emergency Use Listing to Sinopharm Beijing's COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality."

He added: "This expands the list of COVID-19 vaccines that COVAX can buy, and gives countries confidence to expedite their own regulatory approval, and to import and administer a vaccine."

The Sinopharm vaccine joins a list of WHO approved vaccines, in addition to those made by Pfizer, AstraZeneca, Johnson & Johnson and Moderna.

"The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk," said Mariangela Simao, WHO assistant-director general for Access to Health Products. "We urge the manufacturer to participate in the COVAX Facility and contribute to the goal of more equitable vaccine distribution."

The WHO has recommended the jab for people aged 18 to 59 years, in a two-dose schedule with a spacing of three to four weeks.

The organization said the vaccine efficacy for symptomatic and hospitalized disease was estimated to be 79 percent, all age groups combined.?

Experts say the Sinopharm vaccine is easy to store, making it "highly suitable for low-resource settings".

The WHO said it is also the first vaccine that will carry a vaccine vial monitor, a small sticker on the?vaccine vials?that change color as the?vaccine?is exposed to heat, letting health workers know whether the?vaccine?can be safely?used.

Arnaud Didierlaurent, a professor at the University of Geneva's medical school who chairs the advisory group, said it had requested additional studies from Sinopharm, and that there would be "continuous evaluation" of the vaccine and noted that work "does not stop after the listing".

The Sinopharm vaccine has already been authorized by many countries around the world, with some 65 million doses distributed.

Recipients of the vaccine include those in Latin America such as Brazil, Mexico and Chile as well as countries in Asia, including Indonesia, Malaysia and Thailand.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 永仁县| 漳州市| 马龙县| 奉新县| 临安市| 江城| 灵石县| 商城县| 中阳县| 老河口市| 黑龙江省| 南充市| 东城区| 文成县| 阳西县| 夏河县| 天镇县| 高尔夫| 丰县| 孝昌县| 谷城县| 米易县| 龙陵县| 綦江县| 甘德县| 明星| 鹤岗市| 黔南| 平凉市| 万山特区| 营口市| 颍上县| 景洪市| 滦南县| 南投县| 德令哈市| 赤峰市| 腾冲县| 遂昌县| 灵石县| 嘉鱼县|